Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com. Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com. Seaport Therapeutics is seeking a talented and experienced Program Leader (PL) to be an integrative cross-functional leader who is responsible for driving the GlyphAllo Program in order to maximize its future clinical and commercial success in the treatment of depression. This is a highly visible leadership role that bridges scientific, clinical, operational, and commercial disciplines. The GlyphAllo program is currently enrolling a Phase 2b study and the PL will lead the program to execute the current plans within timelines/budget and to plan for future pivotal clinical studies, initial global regulatory filings and pre-commercial activities. He/she will provide leadership across the spectrum of drug development and pre-commercialization activities, ensuring achievement of program and corporate goals. The ideal candidate will be a strategic and entrepreneurial leader well-versed in drug development and commercialization, and a strong influencer who can integrate multiple perspectives effectively and align stakeholders across different functions and levels of the organization. This position requires a presence in the Seaport area of Boston, with a strong preference for being onsite 4 days per week to foster collaboration and effective leadership as the GlyphAllo program grows in complexity and importance. The role will report to the Chief Operating Officer (COO), with strong working relationships with the entire Executive Leadership Team (ELT).
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive